Haploidentical HSCT tolerated by patients with severe anemia

03/14/2013 | Healio

Pediatric patients with severe aplastic anemia were able to tolerate and benefit from haploidentical hematopoietic stem cell transplants, according to a study published in Biology of Blood and Marrow Transplantation. Eleven of the 12 patients who underwent the treatment showed neutrophil engraftment at a median of 10 days following the transplant, researchers said. In one primary engraftment failure case and two graft rejection cases, a second haploidentical hematopoietic stem cell transplant led to a 100% final engraftment rate, the study said. Follow-up at a median of 14.3 months showed all 12 patients were alive and no longer requiring transfusions.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX